Day I:

Tuesday, 2 May 2000

Opening Ceremony

General background and overview:

• Background on GATT and WTO by Mr. M. Kennedy (WTO)

• Intellectual Property Rights by Dr. C. Correa (University of Buenos Aires)

• WHO’s perspective on globalization and access to drugs by Dr. G. Velasquez (WHO)

Lunch

General overview of the TRIPS Agreement by Mr. M. Kennedy (WTO)

WIPO’s role in relation to the TRIPS Agreement by Mr. S. Bhatti (WIPO)

The TRIPS Agreement with a focus on pharmaceuticals - what will change for developing countries by Dr. C. Correa (University of Buenos Aires)

Discussion (panel)

Implications of the TRIPS Agreement for pharmaceuticals:

• Pharmaceutical Industry Perspective

• by Dr. H.E. Bale (IFPMA)

• by Drs. K.A.I Selomulya (GP Farmasi)

• Consumers Perspective by Dr. K. Balasubramaniam (Consumers International)

Discussion (panel)

Day II:

Wednesday, 3 May 2000

Options and choices in patent legislation: compulsory licensing, parallel import and Bolar provision by Mr. J. Love (Consumer Project on Technology)

Implications of the TRIPS Agreement on Biotechnology by Dr. M.D. Nair (Pharmaceutical Industry Consultant)

Traditional medicinal knowledge and Intellectual Property Rights by Mr. S. Bhatti (WIPO)

Discussion (panel)

Trade secrets:

• by Dr. C. Priapantja (Indonesian IPR Society)

• by Dr. C. Correa (University of Buenos Aires)

Trademarks and pharmaceuticals by Mr. J. Love (Consumer Project on Technology)

Discussion (panel)

Lunch

Thailand’s experience with increasing access to HIV/AIDS drugs under TRIPS by Ms. Y. Patanawong (FDA, Thailand)

The implications of the WTO TRIPS Agreement for the pharmaceutical industry in Thailand by Dr. W. S. Janjaroen (Chulalongkorn University, Thailand)

Options and choices in patent legislation: TRIPS compliant but not “TRIPS-plus” by Dr. C. Correa (University of Buenos Aires)

Discussion (panel)

Day III:

Thursday, 4 May 2000

Input from the ASEAN Senior Officials Meeting and the 5^th ASEAN Health Ministers Meeting

Working groups to discuss and draft recommendations

• Working Group 1: Biotechnology and Traditional Medicine
• Working Group 2: Compulsory Licensing, Parallel Import and Bolar Provision

• Working Group 3: Trademarks and Trade Secrets

Lunch

Working Groups (cont.)

Presentation and discussion of draft recommendations (plenary)

Adoption of recommendations